Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure

Alnylam Pharmaceuticals, Inc. experienced a significant decline today, with the stock dropping by 6.65% on October 30, 2025. The stock reached an intraday low of USD 436.51, reflecting a challenging trading session. Over the past week, Alnylam has seen a decrease of 3.11%, while its performance over the last month shows a decline of 1.41%.
Despite these short-term fluctuations, Alnylam has demonstrated strong long-term performance, boasting a remarkable 59.71% increase over the past year and an impressive 91.05% year-to-date gain. The company has consistently outperformed the S&P 500 across various time frames, including a 119.82% increase over the last three years and a substantial 265.59% rise over the past five years.

However, the company faces challenges, including a net profit loss of USD 51.02 million, which has fallen significantly year-over-year. Additionally, the return on capital employed (ROCE) stands at a notably low -257.82%. Despite these hurdles, Alnylam maintains high institutional holdings at 100%, indicating strong backing from sophisticated investors.